LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications
LivaNova PLC - Ordinary Shares (LIVN)
Last livanova plc - ordinary shares earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
livanova.com
Company Research
Source: Business Wire
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned CE Mark approval for ECMO procedures where femoral artery cannulation can be applied. Bi-Flow previously received CE Mark in 2019 for cardiac surgery procedures requiring femoral artery cannulation. Now validated for up to 29 days of use, Bi-Flow ECMO is designed to reduce the risk of limb ischemia for patients receiving ECMO and it allows for safe, easy and reproducible procedures.“After witnessing the potential of Bi-Flow in the cardiac surgery setting, the availability of the cannula for ECMO applications promises to redefine the standard of care for femoral artery cannulation during extracorporeal life support procedures,” said Dr. Paulo Neves from Centro Hospitalar Vila Nova de Gaia in Portugal. “We
Show less
Read more
Impact Snapshot
Event Time:
LIVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIVN alerts
High impacting LivaNova PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
LIVN
News
- LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual MeetingBusiness Wire
- LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea [Yahoo! Finance]Yahoo! Finance
- LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep ApneaBusiness Wire
- A Look at LivaNova's (LIVN) Valuation Following Its Recent 20% Share Price Surge [Yahoo! Finance]Yahoo! Finance
- LivaNova (NASDAQ:LIVN) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
LIVN
Earnings
- 11/5/25 - Beat
LIVN
Sec Filings
- 11/19/25 - Form 4
- 11/18/25 - Form 144
- 11/6/25 - Form SCHEDULE
- LIVN's page on the SEC website